Media

Opportunities and resources for editorial staff

Who We Are

The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. 

The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. 

For interview and media registration requests, please contact media@asgct.org.

Active Media Coverage Opportunities

ASGCT Insights Week

October 16-20, 2023 | Virtual

For editorial staff: FREE access. Contact media@asgct.org. 

Join CGT experts in October for five virtual, two-hour sessions on:

• Revisiting ASGCT's Annual Meeting abstracts

• Risk assessment of lentiviral & AAV gene therapy vectors

• Risk assessment of gene-editing technologies

• Treating genetic diseases prior to birth

• Innate immune responses

View the agenda

Policy Summit 

September 18-19, 2023 | On Demand Until Oct. 23, 2023

For editorial staff: FREE on-demand access for 30 days after the event. Contact media@asgct.org. 

The ASGCT policy and advocacy leaders continuously liaise with major health policy stakeholders, such as FDA, NIH, and Congress. With the Society's advocacy team an established player in the field of gene and cell therapy, our Policy Summit is the opportunity to see top policy and industry leaders come together.

Your complimentary registration would provide access to diverse perspectives on regulatory, legislative, and payment policies that impact gene and cell therapy development.

Speakers include Nicole Verdun, MD (Director of FDA CBER Office of Therapeutic Products (OTP)); Renee Wegrzyn, PhD (Director of the Advanced Research Projects Agency for Health, ARPA-H); and Laura McWright (Center for Medicare & Medicaid Innovation). They'll speak on biomedical innovation, gene therapy access, setting development standards, the Bespoke Gene Therapy Consortium, and more.

View the agenda